Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
3.72 -0.05 -1.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.4 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
99.46% +0.44pp
Institutions
252 +3
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund41.95%
Hedge Fund29.61%
VC/PE Fund15.03%
Public Company9.87%
Individual/Insider8.07%
Government Pension Fund1.40%
Sovereign Wealth Fund0.69%
Private Company0.35%
Family Office/Trust0.32%

Top holders as of 2026-06-30

Avoro Capital Advisors LLC 7.33% · 23.89M sh
RA Capital Management, L.P. 7.23% · 23.56M sh
Paul Manning 6.98% · 22.74M sh
BlackRock 6.95% · 22.65M sh
Vestal Point Capital, LP 5.96% · 19.42M sh
Morgan Stanley Investment Management Inc. 4.83% · 15.72M sh
Morgan Stanley 4.83% · 15.72M sh
Vanguard Capital Management, LLC 4.41% · 14.38M sh
The Goldman Sachs Group, Inc. 4.17% · 13.58M sh
RTW Investments, LP 4.16% · 13.56M sh
FMR 4.16% · 13.56M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 25 buys · 25 sells

NameRoleStake
Paul Manning Board Observer 6.98%
Sean Stalfort Independent Director 0.63%
Sean Nolan Chairperson & CEO 0.20%
Kamran Alam Chief Financial Officer 0.14%
Phillip Donenberg Independent Director 0.07%
Laura Sepp-Lorenzino Independent Director 0.03%
Alison Long Independent Director 0.03%
Sukumar Nagendran President, Head of Research & Development and Director --
Sean McAuliffe Chief Business Officer --
Tiger Lily Capital -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-07-09 Sukumar Nagendran President, Head of Research & Development and Director Automatic Disposition -200,000 $6.24
2026-05-31 Phillip Donenberg Independent Director Other Acquisition +21,335 --
2026-05-31 Phillip Donenberg Independent Director Other Derivative Acquisition +42,671 $5.97
2026-05-31 Sean Stalfort Independent Director Other Acquisition +21,335 --
2026-05-31 Sean Stalfort Independent Director Other Derivative Acquisition +42,671 $5.97
2026-05-31 Laura Sepp-Lorenzino Independent Director Other Acquisition +21,335 --
2026-05-31 Laura Sepp-Lorenzino Independent Director Other Derivative Acquisition +42,671 $5.97
2026-05-31 Alison Long Independent Director Other Acquisition +21,335 --
2026-05-31 Alison Long Independent Director Other Derivative Acquisition +42,671 $5.97
2026-04-09 Sukumar Nagendran President, Head of Research & Development and Director Automatic Disposition -180,979 $4.46
2026-04-09 Sukumar Nagendran President, Head of Research & Development and Director Derivative Exercise and Sale -19,021 $1.71–4.46
2026-02-26 Rumana Haque-Ahmed Chief Regulatory Officer Intent to Sell (Form 144) -2,405 $4.57
2026-02-03 Sean McAuliffe Chief Business Officer Intent to Sell (Form 144) -914 $4.72
2026-02-03 Kamran Alam Chief Financial Officer Open Market Disposition -1,655 $4.52
2026-02-03 Rumana Haque-Ahmed Chief Regulatory Officer Intent to Sell (Form 144) -697 $4.72
2026-01-25 Sean Nolan Chairperson & CEO Open Market Disposition -178,101 $4.61–4.75
2026-01-25 Sukumar Nagendran President, Head of Research & Development and Director Open Market Disposition -116,050 $4.61–4.75
2026-01-25 Kamran Alam Chief Financial Officer Open Market Disposition -102,817 $4.61–4.75
2026-01-22 Sean Nolan Chairperson & CEO Intent to Sell (Form 144) -168,078 $5.09
2026-01-22 Sukumar Nagendran President, Head of Research & Development and Director Intent to Sell (Form 144) -113,824 $5.09

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Taysha Gene Therapies discussion 0 comments

Add a comment